ReviewInternational journal of molecular sciences2020
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Integrative single-cell and spatial transcriptomic approaches to decipher the tumor microenvironment and therapeutic resistance in pancreatic cancer.Cancer biology & therapy · 2026Review
- Identifying diagnostic markers and constructing a prognostic model for pancreatic cancer based on microarray and bioinformatic analysis.Discover oncology · 2026Article
- Signatures of Pancreatic Ductal Adenocarcinoma Uncovered by Integrative Multi-Omics Analysis.Cancers · 2026Article
- Advancing Precision Medicine in PDAC: An Ethical Scoping Review and Call to Action for IHC Implementation.Cancers · 2025Review
- Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients.Journal of experimental & clinical cancer research : CR · 2025Review
- Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer.Pigment cell & melanoma research · 2025Review
- Article
- The RNA world: from experimental laboratory to "in silico" approach. Part 1: User friendly RNA expression databases portals.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2024Review
- Review
- Spheroids of FAP-Positive Cell Lines as a Model for Screening Drugs That Affect FAP Expression.Biomedicines · 2023Article
- Exploiting the molecular subtypes and genetic landscape in pancreatic cancer: the quest to find effective drugs.Frontiers in genetics · 2023Review
- Single-cell transcriptome analysis for cancer and biology of the pancreas: A review on recent progress.Frontiers in genetics · 2023Review
- Synchronous Pancreatic Ductal Adenocarcinoma in the Head and Tail, a Double Trouble: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- Article
- Review
- Article
- GaWRDenMap: a quantitative framework to study the local variation in cell-cell interactions in pancreatic disease subtypes.Scientific reports · 2022Article
- Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)-basis and current status.Ecancermedicalscience · 2022Review
- Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?Cancers · 2021Review
- Identification of prognosis-related molecular subgroups based on DNA methylation in pancreatic cancer.Clinical epigenetics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer represents one of the most lethal disease worldwide but still orphan of a molecularly driven therapeutic approach, although many genomic and transcriptomic classifications have been proposed over the years. Clinical heterogeneity is a hallmark of this disease, as different patients show different responses to the same therapeutic regimens. However, genomic analyses revealed quite a homogeneous disease picture, with very common mutations in four genes only (KRAS, TP53, CDKN2A, and SMAD4) and a long tail of other mutated genes, with doubtful pathogenic meaning. Even bulk transcriptomic classifications could not resolve this great heterogeneity, as many informations related to small cell populations within cancer tissue could be lost. At the same time, single cell analysis has emerged as a powerful tool to dissect intratumoral heterogeneity like never before, with possibility of generating a new disease taxonomy at unprecedented molecular resolution. In this review, we summarize the most relevant genomic, bulk and single-cell transcriptomic classifications of pancreatic cancer, and try to understand how novel technologies, like single cell analysis, could lead to novel therapeutic strategies for this highly lethal disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.